New pharmacological targets in Fanconi Anemia

Autor: Adamo Adele (2), Santonicola Pamela (2), Germoglio Marcello (2), La Volpe Adriana (1), Vettone Antonella (2), Valenti Anna (2), Perugino Giuseppe (2), Ciaramella Maria (2), Faleschini Michela (3), Bottega Roberta (3), De Rocco Daniela (3), Savoia Anna (3)

Publikováno v: fanconi anemia, DNA repair, meiosis, riva del garda, 9-11 marzo 2015
info:cnr-pdr/source/autori:Adamo Adele (2), Santonicola Pamela (2), Germoglio Marcello (2), La Volpe Adriana (1), Vettone Antonella (2), Valenti Anna (2), Perugino Giuseppe (2), Ciaramella Maria (2), Faleschini Michela (3), Bottega Roberta (3), De Rocco Daniela (3), Savoia Anna (3)/congresso_nome:fanconi anemia, DNA repair, meiosis/congresso_luogo:riva del garda/congresso_data:9-11 marzo 2015/anno:2015/pagina_da:/pagina_a:/intervallo_pagine

Fanconi Anemia (FA) is a cancer predisposition syndrome with cells sensitivity to interstrand crosslinking (ICL) agents such as cisplatin (CDDP). Genes in the FA pathway are evolutionary conserved, allowing genetic and molecular studies in the model

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::e031a740bdc1db5950cd997be3f10ce1
http://www.cnr.it/prodotto/i/336661